Ecuphar Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
21
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
- Investments
-
3
Ecuphar General Information
Description
Developer, marketer and distributor of veterinary pharmaceuticals. The company's veterinary pharmaceuticals include OTC and registered products for pets such as dogs, cats, horses, birds as well as for farm animals, enabling the customers to get access to all the pharmaceutical products for their pets in need.
Contact Information
Website
www.ecuphar.comCorporate Office
- Legeweg 157/D
- 8020 Oostkamp
- Belgium
Corporate Office
- Legeweg 157/D
- 8020 Oostkamp
- Belgium
Ecuphar Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ecuphar Patents
Ecuphar Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12208085-B2 | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals | Active | 31-May-2022 | ||
| US-20230381140-A1 | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals | Active | 31-May-2022 | ||
| EP-4029502-A1 | Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals | Pending | 15-Jan-2021 | ||
| ES-2828435-T3 | Compound derived from pyrazoline and its use in a weekly regimen against inflammation and pain derived from degenerative joint disease in mammals | Active | 16-Oct-2014 | ||
| JP-6655625-B2 | Pyrazolin-derived compounds and their use in weekly dosing regimens for inflammation and pain from osteoarthritis in mammals | Active | 16-Oct-2014 | A61K31/415 |
Ecuphar Signals
Ecuphar Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ecuphar Investments (3)
Ecuphar’s most recent deal was a Buyout/LBO with Esteve (Veterinary Division). The deal was made on 05-May-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Esteve (Veterinary Division) | 05-May-2015 | Buyout/LBO | Other Commercial Products | ||
| Riemser Arzneimittel (Veterinary Business) | 29-Jun-2011 | Buyout/LBO | Drug Delivery | ||
| NutriScience | 01-Jan-2009 | Buyout/LBO | Other Consumer Non-Durables |
Ecuphar Exits (1)
Ecuphar’s most recent exit was on 01-Jan-2009 from NutriScience. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| NutriScience | 01-Jan-2009 | Completed |
|
Ecuphar Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ecuphar Veterinary Products | Breda, Netherlands | 2001 | |
| Euracon Pharma Consulting & Trading | Greifswald, Germany | 1995 |
Ecuphar FAQs
-
When was Ecuphar founded?
Ecuphar was founded in 2003.
-
Where is Ecuphar headquartered?
Ecuphar is headquartered in Oostkamp, Belgium.
-
What is the size of Ecuphar?
Ecuphar has 21 total employees.
-
What industry is Ecuphar in?
Ecuphar’s primary industry is Drug Delivery.
-
Is Ecuphar a private or public company?
Ecuphar is a Private company.
-
What is the current valuation of Ecuphar?
The current valuation of Ecuphar is .
-
What is Ecuphar’s current revenue?
The current revenue for Ecuphar is .
-
How much funding has Ecuphar raised over time?
Ecuphar has raised $14.5M.
-
Who are Ecuphar’s investors?
CARDON Pharmaceuticals, Capital@rent, Omega Pharma (Nazareth), Partners at Venture, and Pentahold have invested in Ecuphar.
-
When was Ecuphar acquired?
Ecuphar was acquired on 13-Jul-2017.
-
Who acquired Ecuphar?
Ecuphar was acquired by Animalcare Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process